Cargando…
Immunotherapy in Extensive-Stage Small Cell Lung Cancer
Small cell lung cancer (SCLC) remains a poorly understood disease with aggressive features, high relapse rates, and significant morbidity as well as mortality, yet persistently limited treatment options. For three decades, the treatment algorithm of SCLC has been stagnant despite multiple attempts t...
Autores principales: | El Sayed, Rola, Blais, Normand |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534845/ https://www.ncbi.nlm.nih.gov/pubmed/34677265 http://dx.doi.org/10.3390/curroncol28050347 |
Ejemplares similares
-
Immunotherapy for extensive stage small cell lung cancer
por: Pacheco, Jose M.
Publicado: (2020) -
Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine
por: Tabchi, Samer, et al.
Publicado: (2017) -
Immunotherapy in extensive small cell lung cancer
por: Verma, Vaibhav, et al.
Publicado: (2019) -
Successful Treatment with Brigatinib after Alectinib-Induced Hemolytic Anemia in Patients with Metastatic Lung Adenocarcinoma—A Case Series
por: El Sayed, Rola, et al.
Publicado: (2022) -
Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer
por: Melosky, Barbara L., et al.
Publicado: (2023)